Lilly Restructuring Reflects Belief That Manufacturing Problems Are In The Past
This article was originally published in The Pink Sheet Daily
John Lechleiter is elevated to the position of President and Chief Operating Officer effective Oct. 1.
You may also be interested in...
Settlement will cover approximately 8,000 personal injury claims regarding diabetes and hyperglycemia, or about 75% of the total number of cases, Lilly says. “Lilly is prepared to continue its vigorous defense of Zyprexa in the remaining cases,” the company said.
The district court ruling means that generic versions of olanzapine are unlikely to enter the market before 2011, when the only "Orange Book" listed patent for Zyprexa is set to expire.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter